Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A combination treatment for acute myocardial infarction

A technology for acute myocardial infarction and mortality, applied in drug combinations, pharmaceutical formulations, cardiovascular system diseases, etc.

Inactive Publication Date: 2005-06-08
ORION CORPORATION
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But only using thrombolytic agents to treat myocardial infarction, the mortality rate remains at a high level

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A combination treatment for acute myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1. Intravenous infusion of concentrate

[0043] (a) Levosimone 2.5mg / ml

[0044] (b) Kollidon PF12 10mg / ml

[0045] (c) Citric acid 2mg / ml

[0046] (d) Dehydrated ethanol about 1ml (785mg)

[0047] Preparation of concentrated solution: Add citric acid, Kollidon PF 121 and levosimendan into a sterile preparation container filled with dehydrated ethanol under stirring, and then filter the resulting solution with a 0.22mm sterile filter, and the filtrate is placed in a sterile Distribute into 8ml and 10ml (with 5ml and 10ml transfer) bottles between operations, and seal them with rubber stoppers.

[0048] This concentrated solution needs to be diluted with an aqueous vehicle before intravenous infusion, and is usually diluted with an aqueous isotonic vehicle (such as 5% dextrose aqueous solution or 0.9% sodium chloride aqueous solution) to obtain an aqueous intravenous solution, wherein the amount of levosimendan is usually about Within the range of 0.001-1.0 m...

Embodiment 2

[0049] Example 2. t-PA composition in lyophilized state

[0050] (a)t-PA 2.0% (w / w)

[0051] (b) Phosphoric acid 20% (w / w)

[0052] (c) L-Arginine 78% (w / w)

[0053] The above components are mixed by standard methods, lyophilized and sterilized, including 20 mg, 50 mg, or 100 mg t-PA / dose form (vial) of the lyophilized product reconstituted with sterile water for injection, e.g., to make 1 mg / ml of injection.

example 3

[0054] Example 3: Oral administration of levosimendan composition

[0055] Size 3 Hard Gelatin Capsules

[0056] Levosimone 2.0mg

[0057] Lactose 198mg

[0058] The pharmaceutical preparation in capsule form can be prepared by filling the powder after mixing levosimendan and lactose into capsules made of No. 3 hard gelatin.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A combination therapy for the treatment of acute myocardial infarction comprises administering a combination of a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof to a patient. The combination synergistically reduces mortality of patients with acute myocardial infarction.

Description

technical field [0001] The present invention relates to a method for treating myocardial infarction, that is, co-administering a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof to a patient in need of treatment. The present invention also relates to a pharmaceutical product comprising a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof as a combined preparation. Background of the invention [0002] Myocardial infarction is an important complication characterized by coronary artery disease, usually caused by a sharp drop in coronary blood flow resulting in thrombosis. Thrombolytic therapy, applied intravenously, is widely used, which prevents the reflow of blood to the blocked coronary artery and stores it. Thrombolytics are drugs used to dissolve fibrin-platelet-like thrombi, allowing blood to flow to blood vessels affected by the thrombus. Such thrombolytic agents include streptokinase, urokinase, prourokin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/50A61K38/49A61P7/02A61P9/10
CPCA61K31/50A61K38/49A61P7/02A61P9/10A61K2300/00
Inventor P·波德
Owner ORION CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com